High-dose vitamin C is a vitamin repeatedly infused intravenously, reaching blood levels food or oral supplements cannot, as an add-on to cancer treatment. Evidence is mixed: some studies point toward longer survival, but the largest trial showed no overall gain. Screened patients generally tolerate it; kidney damage, red blood cell destruction and misleading fingerstick glucose readings are uncommon but serious. Abandoning proven treatment carries the greatest risk. (Full Review)
| Marker | Target | Why |
|---|---|---|
| G6PD activity | Normal activity per laboratory | Safety: deficiency stops or limits use |
| Serum creatinine | About 0.6–1.2 mg/dL | Safety: rising values pause use |
| Peak plasma vitamin C | At least 20 mM after infusion | Confirms target blood level |
| Hemoglobin and bilirubin | Hemoglobin about 12–17.5 g/dL; total bilirubin about 0.1–1.2 mg/dL | Safety: signals hemolysis |
| Lactate dehydrogenase | Not specified in the ER | Paired hemolysis check |
| Serum sodium and potassium | Sodium 135–145 mmol/L; potassium 3.5–5.0 mmol/L | Safety: sodium load from sodium ascorbate |
| Ferritin and transferrin saturation | Ferritin about 20–300 ng/mL; transferrin saturation about 20–50% | Safety: iron overload stops or changes use |
| Laboratory venous glucose | Fasting 70–99 mg/dL | Safety: replaces unreliable meters |
| Tumor markers and imaging | No established target; change from own baseline | Disease control |
Cadence: Baseline before the first infusion (G6PD once); creatinine and electrolytes before each infusion for the first 2 weeks, then every 2–4 weeks; post-infusion vitamin C level after each dose step until the target is reached; complete blood count every 2–4 weeks or immediately if urine darkens; tumor markers or imaging every 2–3 months.